- Conditions
- HER2-positive Breast Cancer
- Interventions
- Taxotere, Carboplatin, Herceptin + Pertuzumab, Metformin
- Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Carcinoma
- Interventions
- Carboplatin, Paclitaxel, Bevacizumab, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2036
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Her2-Positive Breast Cancer
- Interventions
- Pertuzumab, Trastuzumab, Paclitaxel, 5-fluorouracil, Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Early Breast Cancer
- Interventions
- EG1206A, Perjeta
- Drug
- Lead sponsor
- EirGenix, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2, Cyclophosphamide 600mg/m^2, Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2, Trastuzumab 8mg/kg and 6 mg/kg, Pertuzumab 840mg and 420mg
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Bloomington, Indiana • New York, New York